COMMENTARY

Thorny Path Ahead toward Trial Rollout of Cost-Effective Assessment in FY2016; Chuikyo to Begin Discussions on May 27

May 26, 2015

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Sovaldi (sofosbuvir) may have received even a higher NHI price if its cost-effectiveness had been assessed - some officials at the Ministry of Health, Labor and Welfare (MLHW) and the Central Social Insurance Medical Council (Chuikyo) said. Gilead Sciences K.K.’s…

To read the full story

HTAs Likely to Be Used for Re-Pricing of Listed Medicines
June 25, 2015

COMMENTARY

Gene Therapies Expand into AMD, Raising Promise and Cost Concerns
April 24, 2026
Challenges in a Post-AG Era: Ensuring a Reliable Supply System
April 6, 2026
Japan’s FY2026 R&D Tax Credit Reform Wins Broad Industry Backing
April 1, 2026
A “Core Industry” in Name Only? Drug Pricing Reform Leaves a Sour Taste
March 24, 2026
Beyond Elevidys: Next-Generation DMD Therapies Advance through Multiple Approaches
March 11, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Gene Therapies Expand into AMD, Raising Promise and Cost Concerns

By Shinya Sato

AAV (adeno-associated virus) gene therapies are moving beyond rare diseases into more prevalent conditions, with neovascular, or wet, age-related macular…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…